Investor Overview

Webcast ImageWebcast
Aimmune Therapeutics at Prescriptions for Success Healthcare Conference  (Live)
12/14/16 at 2:40 p.m. ET
Aimmune Therapeutics at Prescriptions for Success Healthcare Conference
Wednesday, December 14, 2016 2:40 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Our characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens.... more >

Recent Newsmore >
December 1, 2016
Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
— Five Leading Food Allergy Researchers and Clinicians Form Distinguished Board — BRISBANE, Calif.--(BUSINESS WIRE)--Dec. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced the membership of its Scientific Advisory Board, comprised of internationally recognized food allergy experts. ... 
November 28, 2016
Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
— Top-Line PALISADE Data Expected in 4Q 2017 — — New Clinical Study: ARTEMIS Dedicated European Pediatric Trial of AR101 Will Explore Protection at an Endpoint of Tolerating 2,043 mg of Peanut Protein after Nine Months of Treatment — BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatme... 
November 28, 2016
Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced the closing of the $145 million equity investment by Nestlé Health Science. Nestlé Health Science purchased 7,552,084 shares of Aimmune's common stock at $19.20 per share on November 23, 2016, in a... 
Upcoming Eventsmore >
DateTitleRemind
Me
Prior to
Event
December 14, 2016
2:40 p.m. ET
Aimmune Therapeutics at Prescriptions for Success Healthcare Conference
days
Enter your e-mail address 
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.